The OTEZLA® Swedish Website

This site is intended for healthcare professionals.

The OTEZLA® Swedish Website


close x

You are now leaving the Otezla Swedish website!


INTRODUCING OTEZLA®

An oral way to treat Psoriatic Arthritis

  • OTEZLA  has proven efficacy in a broad range of disease manifestations in approved indications, such as symptoms in skin, scalp, nails, pruritus, swollen/tender joints, enthesitis and dactylitis1
  • No cases of reactivation of tuberculosis, and no increased risk vs. placebo for serious infection, cardiovascular events or malignancy in clinical trials1–4
  • OTEZLA is an oral therapy with no label-required prescreening or ongoing laboratory monitoring1
References: 1. OTEZLA SmPC, available via www.ema.europa.eu. 2. Papp K et al, J Am Acad Dermatolog 2015;73:35–49. 3. Kavanaugh A et al. Ann Rheum Dis 2014;73:1020–1026. doi:10.1136/annrheumdis-2013-205056 4. Cather and Horn, Clin Invest 2015; 9: 777–791.

Select an e-mail client to share

close x